Evidence map›Paper›PMID 37600581›Full record

ArticleIranian journal of pathology2023

Molecular Status of

Amirhossein Jafarian, Masoumeh Jafaripour, Masoumeh Gharib, Maryam Salehi, Nema Mohamadian Roshan, Sare Etemad, Khatoone Mirshekar, Maryam Sheikhi, Masoumeh Heidari, Behnaz Ahmadian and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of pathology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Amirhossein JafarianCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Masoumeh JafaripourDepartment of Surgical and Clinical Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Masoumeh GharibDepartment of Surgical and Clinical Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam SalehiDepartment of Pathology, Mashhad University of Medical Sciences, Mashhad, Iran.
Nema Mohamadian RoshanDepartment of Pathology, Mashhad University of Medical Sciences, Mashhad, Iran.
Sare EtemadDepartment of Surgical and Clinical Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Khatoone MirshekarDepartment of Surgical and Clinical Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam SheikhiCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Masoumeh HeidariDepartment of Medical Genetics, School of Medicine, Yazd University of Medical Sciences, Yazd, Iran.
Behnaz AhmadianCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Zahra KhoshnegahCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Hossein AyatollahiCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Payam SiyadatCancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mashhad University of Medical Sciences · IRIran University of Medical Sciences · IRYazd University · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Objective: Epithelial ovarian cancer (EOC) is the most prevalent type of ovarian cancer. Previous studies have elucidated different pathways for the progression of this malignancy. The mutation in the B-Raf proto-oncogene, serine/threonine kinase (BRAF) gene, a member of the MAPK/ERK signaling pathway, plays a role in the development of EOC. The current study aimed to determine the frequency of the BRAF V600E mutation in ovarian serous and mucinous tumors, including borderline and carcinoma subtypes. Methods: A total of 57 formalin-fixed paraffin-embedded samples, including serous borderline tumors (SBTs), low-grade serous carcinomas (LGSCs), high-grade serous carcinomas (HGSCs), mucinous borderline tumors (MBTs), and mucinous carcinomas, and 57 normal ovarian tissues were collected. The BRAF V600E mutation was analyzed using polymerase chain reaction (PCR) and sequencing. Results: While 40% of the SBT harbor Conclusion: The

Indexed as

BRAF V600E mutationDirect sequencingEpithelial ovarian cancer

Identifiers

PMID37600581
PMCPMC10439751
OpenAlexW4383561817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.